205 related articles for article (PubMed ID: 27866772)
1. H1:IC31 vaccination is safe and induces long-lived TNF-α
Mearns H; Geldenhuys HD; Kagina BM; Musvosvi M; Little F; Ratangee F; Mahomed H; Hanekom WA; Hoff ST; Ruhwald M; Kromann I; Bang P; Hatherill M; Andersen P; Scriba TJ;
Vaccine; 2017 Jan; 35(1):132-141. PubMed ID: 27866772
[TBL] [Abstract][Full Text] [Related]
2. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults.
Luabeya AK; Kagina BM; Tameris MD; Geldenhuys H; Hoff ST; Shi Z; Kromann I; Hatherill M; Mahomed H; Hanekom WA; Andersen P; Scriba TJ; ; Schoeman E; Krohn C; Day CL; Africa H; Makhethe L; Smit E; Brown Y; Suliman S; Hughes EJ; Bang P; Snowden MA; McClain B; Hussey GD
Vaccine; 2015 Aug; 33(33):4130-40. PubMed ID: 26095509
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials.
Norrby M; Vesikari T; Lindqvist L; Maeurer M; Ahmed R; Mahdavifar S; Bennett S; McClain JB; Shepherd BM; Li D; Hokey DA; Kromann I; Hoff ST; Andersen P; de Visser AW; Joosten SA; Ottenhoff THM; Andersson J; Brighenti S
Vaccine; 2017 Mar; 35(12):1652-1661. PubMed ID: 28216183
[TBL] [Abstract][Full Text] [Related]
4. The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial.
Geldenhuys H; Mearns H; Miles DJ; Tameris M; Hokey D; Shi Z; Bennett S; Andersen P; Kromann I; Hoff ST; Hanekom WA; Mahomed H; Hatherill M; Scriba TJ; ; van Rooyen M; Bruce McClain J; Ryall R; de Bruyn G;
Vaccine; 2015 Jul; 33(30):3592-9. PubMed ID: 26048780
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial.
Reither K; Katsoulis L; Beattie T; Gardiner N; Lenz N; Said K; Mfinanga E; Pohl C; Fielding KL; Jeffery H; Kagina BM; Hughes EJ; Scriba TJ; Hanekom WA; Hoff ST; Bang P; Kromann I; Daubenberger C; Andersen P; Churchyard GJ
PLoS One; 2014; 9(12):e114602. PubMed ID: 25490675
[TBL] [Abstract][Full Text] [Related]
6. Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial.
Suliman S; Luabeya AKK; Geldenhuys H; Tameris M; Hoff ST; Shi Z; Tait D; Kromann I; Ruhwald M; Rutkowski KT; Shepherd B; Hokey D; Ginsberg AM; Hanekom WA; Andersen P; Scriba TJ; Hatherill M;
Am J Respir Crit Care Med; 2019 Jan; 199(2):220-231. PubMed ID: 30092143
[TBL] [Abstract][Full Text] [Related]
7. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers.
van Dissel JT; Arend SM; Prins C; Bang P; Tingskov PN; Lingnau K; Nouta J; Klein MR; Rosenkrands I; Ottenhoff TH; Kromann I; Doherty TM; Andersen P
Vaccine; 2010 Apr; 28(20):3571-81. PubMed ID: 20226890
[TBL] [Abstract][Full Text] [Related]
8. The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3).
Churchyard GJ; Snowden MA; Hokey D; Dheenadhayalan V; McClain JB; Douoguih M; Pau MG; Sadoff J; Landry B
Vaccine; 2015 Apr; 33(15):1890-6. PubMed ID: 25698492
[TBL] [Abstract][Full Text] [Related]
9. Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen.
Skeiky YA; Dietrich J; Lasco TM; Stagliano K; Dheenadhayalan V; Goetz MA; Cantarero L; Basaraba RJ; Bang P; Kromann I; McMclain JB; Sadoff JC; Andersen P
Vaccine; 2010 Jan; 28(4):1084-93. PubMed ID: 19896449
[TBL] [Abstract][Full Text] [Related]
10. Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis.
Bennekov T; Dietrich J; Rosenkrands I; Stryhn A; Doherty TM; Andersen P
Eur J Immunol; 2006 Dec; 36(12):3346-55. PubMed ID: 17109467
[TBL] [Abstract][Full Text] [Related]
11. A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area.
Hussein J; Zewdie M; Yamuah L; Bedru A; Abebe M; Dagnew AF; Chanyalew M; Yohannes AG; Ahmed J; Engers H; Doherty TM; Bang P; Kromann I; Hoff ST; Aseffa A
Trials; 2018 Jan; 19(1):24. PubMed ID: 29321075
[TBL] [Abstract][Full Text] [Related]
12. Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection.
van Dissel JT; Soonawala D; Joosten SA; Prins C; Arend SM; Bang P; Tingskov PN; Lingnau K; Nouta J; Hoff ST; Rosenkrands I; Kromann I; Ottenhoff TH; Doherty TM; Andersen P
Vaccine; 2011 Mar; 29(11):2100-9. PubMed ID: 21256189
[TBL] [Abstract][Full Text] [Related]
13. Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose.
Aagaard C; Hoang TT; Izzo A; Billeskov R; Troudt J; Arnett K; Keyser A; Elvang T; Andersen P; Dietrich J
PLoS One; 2009 Jun; 4(6):e5930. PubMed ID: 19529771
[TBL] [Abstract][Full Text] [Related]
14. A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates.
Rodo MJ; Rozot V; Nemes E; Dintwe O; Hatherill M; Little F; Scriba TJ
PLoS Pathog; 2019 Mar; 15(3):e1007643. PubMed ID: 30830940
[TBL] [Abstract][Full Text] [Related]
15. Recombinant bacille Calmette-Guerin coexpressing Ag85b, CFP10, and interleukin-12 elicits effective protection against Mycobacterium tuberculosis.
Chen YY; Lin CW; Huang WF; Chang JR; Su IJ; Hsu CH; Cheng HY; Hsu SC; Dou HY
J Microbiol Immunol Infect; 2017 Feb; 50(1):90-96. PubMed ID: 25732698
[TBL] [Abstract][Full Text] [Related]
16. Antiviral Innate Immune Activation in HIV-Infected Adults Negatively Affects H1/IC31-Induced Vaccine-Specific Memory CD4+ T Cells.
Lenz N; Schindler T; Kagina BM; Zhang JD; Lukindo T; Mpina M; Bang P; Kromann I; Hoff ST; Andersen P; Reither K; Churchyard GJ; Certa U; Daubenberger CA
Clin Vaccine Immunol; 2015 Jul; 22(7):688-96. PubMed ID: 25924764
[TBL] [Abstract][Full Text] [Related]
17. Alarmin IL-33 elicits potent TB-specific cell-mediated responses.
Villarreal DO; Siefert RJ; Weiner DB
Hum Vaccin Immunother; 2015; 11(8):1954-60. PubMed ID: 26091147
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of immune response to a DNA vaccine against Mycobacterium tuberculosis Ag85B by incorporation of an autophagy inducing system.
Meerak J; Wanichwecharungruang SP; Palaga T
Vaccine; 2013 Jan; 31(5):784-90. PubMed ID: 23228812
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting.
Penn-Nicholson A; Geldenhuys H; Burny W; van der Most R; Day CL; Jongert E; Moris P; Hatherill M; Ofori-Anyinam O; Hanekom W; ; Bollaerts A; Demoitie MA; Kany Luabeya AK; De Ruymaeker E; Tameris M; Lapierre D; Scriba TJ
Vaccine; 2015 Jul; 33(32):4025-34. PubMed ID: 26072017
[TBL] [Abstract][Full Text] [Related]
20. Sequential pulmonary immunization with heterologous recombinant influenza A virus tuberculosis vaccines protects against murine M. tuberculosis infection.
Muflihah H; Flórido M; Lin LCW; Xia Y; Triccas JA; Stambas J; Britton WJ
Vaccine; 2018 Apr; 36(18):2462-2470. PubMed ID: 29602704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]